Danaher Corporation
As of Oct 22, 2026, Danaher is in Stage 2, the uptrend phase, now in week 7 (since Sep 10, 2026). It closed at $229.75, 4.5% below its 52-week high and above its 200-day average, which is falling.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is DHR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
DHR among Diagnostics & Research26th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …26 | DHR | Stage 2 · wk 7 | 59 | +3.9% |
Danaher: quick answers
What stage is Danaher in?
As of Oct 22, 2026, Danaher (DHR) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Danaher in an uptrend?
Yes. Danaher is in a Stage 2 uptrend. It trades 14.6% above its 200-day average, which is falling.
How far is Danaher from its 52-week high?
Danaher closed at $229.75 on Oct 22, 2026, 4.5% below its 52-week high of $240.61. Its 52-week low is $161.29.
How has Danaher performed over the past year?
As of Oct 22, 2026, Danaher is up 4.8% over the past year and up 0.3% so far in 2026.
Which sector and industry is Danaher in?
Danaher is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.